DFDA

Lubiprostone

Treatment for Irritable Bowel Syndrome

Typical Dosage: 8 mcg orally twice daily

Effectiveness
60%
Safety Score
75%
Clinical Trials
8
Participants
7K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
75
DangerousModerateSafe
Treatment Details
Dosage Range
8 mcg orally twice daily
Time to Effect
1-2 weeks
Treatment Duration
Long-term (chronic)
Evidence Quality
HIGH
Number Needed to Treat (NNT)
7(Treat 7 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
4(Treat 4 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$10,000
Monitoring:$300
Side Effect Mgmt:$250
Total Annual:$10,550
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATE
ICER
$100,000/QALY
QALYs Gained
0.07
Outcome-Based Costs
Cost per Responder
$37,679
Cost per Remission
$87,917
Prescription Access Economics
Annual Societal Loss per Patient
$8,110
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$250/year
Time Cost
$120/year
Travel + wait time
Insurance Admin Cost
$40/year
Prior auth, claims
Rx Price
$10,000/year
Potential OTC Price
$2,000/year
Estimated if OTC available
Early Treatment Benefit
+0.05 QALYs
From faster OTC access
Risk Assessment
Misuse Risk
LOW
Missed Diagnosis Risk
MODERATE
Lubiprostone Outcomes

for Irritable Bowel Syndrome

Efficacy Outcomes
Overall Effectiveness
+60%
Response Rate
+28%
Remission Rate
+12%
Common Side Effects
Nausea
+23%
Diarrhea
+13%
Abdominal pain
+8%

Sources:

nih.gov
nih.gov
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov

Completed Clinical Trials
6 completed trials for Lubiprostone in Irritable Bowel Syndrome

Lubiprostone Effects on Visceral Pain Sensitivity

NCT01166789COMPLETEDPHASE1
View Study
62 participants
INTERVENTIONAL
Chapel Hill, United States
Started: Feb 1, 2008

Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation

NCT00399542COMPLETEDPHASE3
View Study
581 participants
INTERVENTIONAL
Started: May 1, 2005

Intestinal Microecology in Chronic Constipation

NCT00934479COMPLETEDPHASE1
View Study
21 participants
INTERVENTIONAL
Scottsdale, United States
Started: Apr 1, 2010

Effect of Lubiprostone on Small Bowel Contractions in Female Patients With Constipation Irritable Bowel Syndrome (C-IBS)

NCT01085643COMPLETEDNA
View Study
4 participants
INTERVENTIONAL
Los Angeles, United States
Started: Mar 1, 2010

Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation

NCT00380250COMPLETEDPHASE3
View Study
590 participants
INTERVENTIONAL
Started: May 1, 2005

Effects of Lubiprostone on Gastrointestinal Transit & pH in Irritable Bowel Syndrome (IBS) With Constipation

NCT01162863COMPLETEDNA
View Study
60 participants
INTERVENTIONAL
Ann Arbor, United States
Started: Nov 1, 2010